Abstract
In this issue of Blood, articles by Manne et al and Hottz et al highlight platelet hyperactivity in COVID-19–associated pathophysiology.(,) Although the hallmarks of COVID-19 include a brisk inflammatory response and respiratory symptoms, the hematologic manifestations of this infection have also garnered attention, with thrombotic complications taking center stage.(,) COVID-19–associated coagulopathy has been characterized by an elevated D-dimer, mild thrombocytopenia, and a prolongation of the activated partial thromboplastin time. Alongside these laboratory abnormalities, patients present with increased rates of thrombosis. The role of platelets in the thrombotic complications of COVID-19 is explored in these 2 articles, establishing that platelet hyperactivity contributes to the coagulopathy seen in COVID-19.